Novo Nordisk A/S (NYSE:NVO) Shares Sold by YHB Investment Advisors Inc.

YHB Investment Advisors Inc. lessened its stake in Novo Nordisk A/S (NYSE:NVO) by 26.3% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 2,419 shares of the company’s stock after selling 865 shares during the period. YHB Investment Advisors Inc.’s holdings in Novo Nordisk A/S were worth $208,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Novare Capital Management LLC lifted its stake in Novo Nordisk A/S by 3.2% in the 3rd quarter. Novare Capital Management LLC now owns 2,727 shares of the company’s stock valued at $325,000 after buying an additional 85 shares in the last quarter. Rosenberg Matthew Hamilton raised its holdings in shares of Novo Nordisk A/S by 2.5% in the third quarter. Rosenberg Matthew Hamilton now owns 3,812 shares of the company’s stock worth $454,000 after acquiring an additional 94 shares during the last quarter. Burns J W & Co. Inc. NY lifted its position in shares of Novo Nordisk A/S by 1.9% in the third quarter. Burns J W & Co. Inc. NY now owns 5,430 shares of the company’s stock valued at $647,000 after acquiring an additional 100 shares in the last quarter. Spinnaker Trust boosted its stake in shares of Novo Nordisk A/S by 1.1% during the third quarter. Spinnaker Trust now owns 9,615 shares of the company’s stock valued at $1,145,000 after acquiring an additional 100 shares during the last quarter. Finally, Marco Investment Management LLC increased its position in Novo Nordisk A/S by 1.5% during the 3rd quarter. Marco Investment Management LLC now owns 6,702 shares of the company’s stock worth $798,000 after purchasing an additional 100 shares in the last quarter. 11.54% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

NVO has been the topic of a number of recent research reports. Cantor Fitzgerald restated an “overweight” rating and issued a $160.00 target price on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. BMO Capital Markets decreased their target price on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a research report on Monday, December 23rd. BNP Paribas raised shares of Novo Nordisk A/S to a “strong-buy” rating in a research note on Monday, December 2nd. Sanford C. Bernstein upgraded Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a report on Monday, January 6th. Finally, UBS Group upgraded Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research note on Wednesday, January 8th. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Novo Nordisk A/S currently has a consensus rating of “Buy” and a consensus target price of $145.25.

Novo Nordisk A/S Stock Performance

NYSE:NVO opened at $85.00 on Wednesday. Novo Nordisk A/S has a fifty-two week low of $78.17 and a fifty-two week high of $148.15. The firm’s 50 day moving average is $95.10 and its two-hundred day moving average is $114.43. The company has a market cap of $381.45 billion, a P/E ratio of 27.51, a P/E/G ratio of 0.90 and a beta of 0.45. The company has a quick ratio of 0.75, a current ratio of 0.94 and a debt-to-equity ratio of 0.43.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.